Press releases
These press releases are intended for journalists and analysts/investors.
-
The three letters making Australian men disappear
There’s a disease affecting one in three Australian men over 50
-
GSK confirms that Bexsero (meningococcal B vaccine) will be available for purchase in Australia next week
GSK has increased supply by an additional 200,000 doses of Bexsero (meningococcal B vaccine) which can be ordered
-
Access to Breo Ellipta for respiratory patients on the PBS is unchanged
Breo Ellipta PBS listing updated to recognise fluticasone furoate as a distinct medicine from fluticasone propionate from 1 June 2017
-
GSK transfers Ultiva to Aspen in Australia
GlaxoSmithKline Australia Pty Ltd (GSK) is formally transferring Ultiva (remifentanil), an anaesthetic, to Aspen Pharmacare Australia
-
Bexsero (meningococcal B) vaccine availability
While we increased supply of Bexsero (meningococcal B) vaccine significantly this year, it still isn’t meeting demand and we have been
-
GSK welcomes Medicines Australia strategic agreement
GlaxoSmithKline (GSK) Australia welcomes the Government’s commitment to the Medicines Australia strategic agreement
-
Collaboration and mentorship prove winning formula for manufacturing
Collaboration between business and education is critical for a strong Australian medicine manufacturing industry
-
GSK Australia Reports 2016 results to ASIC
GlaxoSmithKline (GSK) Australia has reported its 2016 results to the Australian Securities and Investment Commission (ASIC)
-
Statement on arachnoiditis and myelograms
GSK has the utmost sympathy for the people who are afflicted by arachnoiditis. It can be a very debilitating and painful condition
-
GSK responds to Cyclone Debbie
GSK has responded to the Queensland Cyclone Debbie emergency relief by providing two pharmacies in Bowen and Airlie Beach with a donation
-
Availability of Menveo (meningococcal ACWY vaccine)
GSK is experiencing a short-term supply constraint of Menveo® in Australia due to a recent increase in notifications of the meningococcal
-
GSK discloses $28,375 in payments to HCPs
GSK stopped paying healthcare professionals to speak about our prescription medicines and vaccines on 1 January 2016
-
GSK increases supply of Meningococcal B vaccine
Recently there has been a global increase in demand for Bexsero (meningococcal B) vaccine which is reflected in Australia as well
-
New research shows Australians aren’t taking ageing lying down
Over 50s keep up with active-wear obsessed millennials on the activity stakes*
-
New treatment option available January 1 2017 for patients with a form of severe asthma
First therapy approved for severe refractory eosinophilic asthma to be listed on the PBS
-
Santa’s prostate nightmare urges Australian men to act
What would happen to Christmas if Santa suffered prostate issues?
-
GSK invests to support female technology entrepreneurs
GSK Australia announced today that it will support BlueChilli’s ‘SheStarts’
-
GSK Consumer Healthcare to close Ermington manufacturing site in 2020
All entitlements are protected for the 223 employees whose jobs are affected, and the company will work through the next four years
-
Bexsero (Meningococcal B) vaccine availability (1)
Recently there has been a global increase in demand for Bexsero® (meningococcal B) vaccine which is reflected in Australia as well
-
GSK founding partner for Victorian Medicines Manufacturing Innovation Centre
GSK Australia today announced its financial and in-kind support for the Medicine Manufacturing Innovation Centre (MMIC)
